Literature DB >> 3278498

Intravenous indomethacin prevents venipuncture inflammatory sequelae.

A Hiller1, M Pitkänen, M Tuominen, P H Rosenberg.   

Abstract

One hundred general or orthopaedic surgery patients (ASA I-II) were randomly given either indomethacin (25-50 mg bolus plus infusion, 5-7.5 mg h-1) in lactated Ringer solution intravenously in one hand and only lactated Ringer solution into a corresponding vein of the other hand (50 patients) or only lactated Ringer solution intravenously in both hands (50 patients), starting before anaesthesia induction and ending at 7 a.m. the following morning. All anaesthetic drugs were given equally divided into both drips. The need for additional analgesia as well as venipuncture and infusion sequelae were registered on the postoperative morning in a double-blind fashion. The mean +/- s.d. oxycodone dose in the postoperative observation period was lower in the indomethacin group (18 +/- 16 mg) than in the control group (27 +/- 20 mg) (n.s.). There was a lower number of patients requiring oxycodone more than once in the indomethacin group than in the control group (P less than 0.05). Fewer patients in the indomethacin group (22%) had inflammatory changes at the venipuncture site than in the control group (46%) (P less than 0.05). There was no difference between hands; i.e. in patients given indomethacin inflammatory changes were equally common in both hands. No thrombophlebitic complications developed, which was confirmed by a mailed questionnaire (response 96/100) 2 weeks after surgery.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3278498     DOI: 10.1111/j.1399-6576.1988.tb02681.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  1 in total

Review 1.  Do the pharmacodynamics of the nonsteroidal anti-inflammatory drugs suggest a role in the management of postoperative pain?

Authors:  L E Mather
Journal:  Drugs       Date:  1992       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.